For about 25 million Americans who suffer from obstructive sleep apnea, there are various effective treatments such as CPAP ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

Major health insurance providers in India — both public and private — exclude sleep disorders from their plans. This coverage ...

Truly, you'll find me snuggled up in my bed whenever the opportunity arises, and I'm always down to go try some delicious new ...

What many dismiss as a mere nighttime nuisance often signals deeper health issues requiring medical attention. While snoring ...

WAKE-UP CALL: 104m Indians or 11% of the population suffer from obstructive sleep apnea, according to a 2023 AIIMS study ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

The sleep disorders center at Bradford Regional Medical Center achieved a milestone in patient care by completing over 1,000 ...

According to the Centers for Disease Control and Prevention, roughly one in three adults in the U.S. don’t get enough rest or sleep every day. Meanwhile, an estimated 50 million to 70 million people ...

Dronabinol + palmidrol is under clinical development by Evero Health and currently in Phase II for Tourette Syndrome.

Zepbound, a drug approved by the FDA, has been shown to reduce the severity of obstructive sleep apnea in obese adults, ...